IL308223A - Prevention of eosinophilic traps - Google Patents

Prevention of eosinophilic traps

Info

Publication number
IL308223A
IL308223A IL308223A IL30822323A IL308223A IL 308223 A IL308223 A IL 308223A IL 308223 A IL308223 A IL 308223A IL 30822323 A IL30822323 A IL 30822323A IL 308223 A IL308223 A IL 308223A
Authority
IL
Israel
Prior art keywords
seq
antibody
amino acid
acid sequence
chain variable
Prior art date
Application number
IL308223A
Other languages
English (en)
Hebrew (he)
Inventor
Es Helmuth Hendrikus Gerardus Van
Renato Gerardus Silvano Chirivi
Daphne Montizaan
Eric Charles Meldrum
Original Assignee
Citryll B V
Es Helmuth Hendrikus Gerardus Van
Renato Gerardus Silvano Chirivi
Daphne Montizaan
Eric Charles Meldrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21172160.0A external-priority patent/EP4085973A1/en
Application filed by Citryll B V, Es Helmuth Hendrikus Gerardus Van, Renato Gerardus Silvano Chirivi, Daphne Montizaan, Eric Charles Meldrum filed Critical Citryll B V
Publication of IL308223A publication Critical patent/IL308223A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL308223A 2021-05-04 2022-05-04 Prevention of eosinophilic traps IL308223A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21172160.0A EP4085973A1 (en) 2021-05-04 2021-05-04 Inhibition of eosinophil extracellular traps
GB202111541 2021-08-11
PCT/EP2022/061970 WO2022233931A1 (en) 2021-05-04 2022-05-04 Inhibition of eosinophilic traps

Publications (1)

Publication Number Publication Date
IL308223A true IL308223A (en) 2024-01-01

Family

ID=81392799

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308223A IL308223A (en) 2021-05-04 2022-05-04 Prevention of eosinophilic traps

Country Status (9)

Country Link
US (1) US20250084154A1 (https=)
EP (1) EP4333981A1 (https=)
JP (1) JP2024521638A (https=)
KR (1) KR20240005856A (https=)
AU (1) AU2022270356A1 (https=)
CA (1) CA3215452A1 (https=)
IL (1) IL308223A (https=)
MX (1) MX2023013021A (https=)
WO (1) WO2022233931A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage
GB202318703D0 (en) 2023-12-07 2024-01-24 Citryll B V Diagnostic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
NO2294086T3 (https=) 2008-06-04 2018-02-10
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
JP7037940B2 (ja) 2014-12-11 2022-03-17 シトリル べー．フェー． 特発性肺線維症の治療方法
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4

Also Published As

Publication number Publication date
MX2023013021A (es) 2024-02-12
KR20240005856A (ko) 2024-01-12
AU2022270356A1 (en) 2023-09-14
JP2024521638A (ja) 2024-06-04
US20250084154A1 (en) 2025-03-13
CA3215452A1 (en) 2022-11-10
WO2022233931A1 (en) 2022-11-10
EP4333981A1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
US12590143B2 (en) Antibodies binding to citrullinated histone 2A and/or 4
US20250084154A1 (en) Inhibition of eosinophilic traps
JP2020188765A (ja) Ｌｏｘ１特異的結合タンパク質及びその使用
CN120092020A (zh) Cnx抗原结合分子
US10513561B2 (en) Anti-MYL9 antibody
US12600778B2 (en) Rage antibodies, fragments and uses thereof
EP3682898A1 (en) Pharmaceutical composition comprising antibody binding specifically to lysyl-trna synthetase n-terminus as effective ingredient for preventing or treating immune cell migration-related disease
EP4085973A1 (en) Inhibition of eosinophil extracellular traps
CN117396221A (zh) 嗜酸性粒细胞陷阱的抑制
EA052640B1 (ru) Ингибирование внеклеточных ловушек
US20210277108A1 (en) Blood brain barrier selective antibodies and methods of use
EP4442705A1 (en) Dosage
JP2026513830A (ja) 用量
WO2025120152A1 (en) Diagnostic agent
HK40128527A (en) Antibodies binding to citrullinated histone 2a and/or 4
HK40017344B (en) Antibodies to amyloid beta
HK40017344A (en) Antibodies to amyloid beta